Stockscreener 앱 받기
0.961
3.04%
-0.0301
시간 외 거래:
.97
0.009
+0.94%
Revelation Biosciences Inc 주식(REVB)의 최신 뉴스
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate
Revelation Biosciences expands AKI advisory board - Investing.com UK
Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView
Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan
Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com
Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com
REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com
Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate
REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate
REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate
Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate
REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser
Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser
REVB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Awaits Clinical MilestonesEPS Surprise History - The Legal Advocate
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet - Bez Kabli
Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo
Revelation Biosciences (REVB) Climbs +4.51% — Resistance at $1.07 in Focus 2026-05-18Community Risk Signals - Newser
Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal
Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan
Revelation Biosciences announces pricing of $4M public offering - MSN
TradingKey - TradingKey
REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill
Revelation Biosciences (NASDAQ: REVB) seeks wide reverse split authority in 2026 proxy - Stock Titan
Revelation Biosciences releases proxy materials with CEO update - Investing.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - The Joplin Globe
How one 300-patient trial could unlock a new acute kidney injury treatment - Stock Titan
The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08Verified Stock Signals - Newser
EX-99.1 - SEC.gov
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - Times Argus
Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed - Stock Titan
FDA agrees to single Gemini study for acute kidney injury - Stock Titan
BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71 - TradingView
Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge - Stock Titan
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
1.27%
1.43%
자본화:
|
볼륨(24시간):